Stocks · US
ALNY
XNAS
Alnylam Pharmaceuticals, Inc.
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E36.42x
P/B21.73x
P/S6.12x
EPS$6.04
ROE59.67%
ROA14.54%
Dividend yield0.00%
EV/EBITDA27.24x
Debt/Equity0.75
Free cash flow$794M
Returns and 52-week range
1W-11.86%
1M-15.85%
3M-30.78%
6M-29.91%
1Y-50.93%
YTD-44.04%
52W high$495.55
52W low$197.81
From 52W high-54.81%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| ZOETIS INC. | $29.5B | 11.28 | 9.37 | -5.91% |
| West Pharmaceutical Services, Inc. | $26.5B | 46.94 | 8.87 | +9.61% |
| Mettler-Toledo International | $30.9B | 34.11 | 2,408.87 | +13.96% |
| Roivant Sciences Ltd. Common Shares | $25.8B | — | 6.11 | +1.72% |
| Alcon Inc. Ordinary Shares | $31.1B | 70.68 | 1.59 | -10.37% |
| 퀘스트 다이어그노스틱스 | $25.6B | 24.20 | 3.41 | -3.69% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.